Bioceltix joins the Warsaw Stock Exchange Academy

Members of Bioceltix Management Board have decided to take part in the Warsaw Stock Exchange Growth Academy. This is the second edition of the program organized by the WSE.

It aims to build the competences of leaders who want to take their business to the next level.

We believe that our participation in the workshops organized as part of the Academy will help us to better manage the company and introduce state-of-the-art solutions which have already been tested by other organizations.

Until June 2021, 24 participants of the Academy, including us, will be taking part in a series of ten sessions and numerous accompanying events.

Wrote about us

Puls Biznesu

Puls Biznesu about our plans: Bioceltix announces that it will soon debut on NewConnect – the company has recently completed the pre-IPO round. So far, the company has obtained a total of approx. PLN 20 million in financing for the development of a still innovative method of treating pets ...

Article

Forbes- Incredibles

Forbes about Polish start-ups in the coronavirus crisis: “The year 2020 was a big challenge for companies, individual sectors of the economy and probably all of us. In the coming weeks and months of 2021 it will be similar. The condition of start-ups is no exception here. it is easier and ...

Article

Investors’ Zone

According to the „Investors’ Zone”, an interesting year is being prepared on the stock exchange: “This year, an exceptionally large group of companies is choosing NewConnect. As many as 63 companies declared their willingness to enter the alternative market, and several more in the ...

Article

Portal Wrocław

Gazeta Wrocławska wrote about us: “Bioceltix is ​​working on innovative biological medicines used in the treatment of common autoimmune and inflammatory diseases in companion animals. The company from Wrocław has something to fight for. This is indicated by the numbers on the global drug ...

Article

Mam Startup – summary 2021

We create at Bioceltix veterinary biological medicines, and in 2020 we announced plans for a stock exchange debut and we obtained a permit from the Main Pharmaceutical Inspector to manufacture veterinary biological drugs. Despite the pandemic, we continue our projects without downtime. You can ...

Article